

1 .  
" .  
EXPRESS MAIL NO. EV331816097US

PATENT APPLICATION

File No: 97-72C3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Darrell C. Conklin, Betty A. Haldeman  
Serial No. :  
Group Art Unit :  
Examiner :  
Filed : February 27, 2004  
For : MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10  
Date Submitted : February 27, 2004

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

The present application is a continuation of U.S. Patent Application No. 10/413,661, filed April 15, 2003; which is a continuation of U.S. Patent Application No. 09/199,586, filed November 25, 1998, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/066,597, filed November 26, 1997.

Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent Office in a prior application identified herein.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 26-0290.

The Examiner is invited to contact the Undersigned at the below-listed telephone number, if there are any questions concerning this paper.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Shelby J. Walker". The signature is fluid and cursive, with a long horizontal stroke at the end.

Shelby J. Walker  
Registration No. 45,192  
(206) 442-6558

**FORM PTO 1449**  
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE**  
**PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(Use several sheets if necessary)

File No. 97-72C3

Serial No.

Applicant(s):  
Darrell C. Conklin, Betty A. Haldeman

Filing Date:  
February 27, 2004

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,723,299	3/98	Bell et al.	435	7.1	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A2		Incyte Pharmaceuticals Inc., INC819592, March 5, 1996.
	A3		Incyte Pharmaceuticals Inc., INC4304592, July 9, 1998.
	A4		Wuyts et al., "Isolation of the CXC chemokines ENA-78, GRO $\alpha$ and GRO $\gamma$ from tumor cells and leukocytes reveals NH <sub>2</sub> -terminal heterogeneity. Functional comparison of different natural isoforms," <u>Eur J. Biochem</u> 260:421-429, 1999.
	A5		Rohovsky et al., "Growth factors and angiogenesis in wound healing," Growth Factors Would Healing, Eds: Ziegler T.R., Pierce G.F., Herndon D.N.; Pub: Springer New York N.Y., pages 8-26, 1997.
	A6		Diavin, "Cytokines and tissue repair," <u>J. Immunol. Immunopharmacol</u> 17(1):25-29, 1997.
	A7		George et al., "Macromolecular Sequencing & Synthesis," pages 127-149, Ch. 12, Alan R. Liss, Inc., 1988.
	A8		Harlow et al., "Antibodies A Laboratory Manual," page 76, Ch. 5, Cold Springs Harbor Laboratory, 1988.
	A9		Cunningham et al., <u>Science</u> 244:1081-1085, 1989.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.